- Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study
- John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension
- With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive
- This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows the company’s Investigational New Drug (“IND”) application earlier in the year.
The HYPER-H23-1 clinical trial, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will seek to explore the overall effectiveness of its patented…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer
CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is powered by IBN
